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patency at 12-months compared with BA with a trend toward
improved outcomes for DES and BMS compared with BA. Head to head
comparison for DCB vs stenting strategies is warranted.
CATEGORIES ENDOVASCULAR: Peripheral Vascular Disease and In-
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BACKGROUND Endovascular occlusion of blood vessels represents a
key component of interventional therapy. While coils are most
commonly used, vessel occlusion is generally not achieved immedi-
ately and may necessitate a large number of devices. It has been
suggested that endovascular plugs may overcome these limitations;
however, immediate and durable occlusion remains a challenge with
plugs as well. This study evaluates a newly designed endovascular
occlusion system (ArtVentive EOS).
METHODS The EOS combines a nitinol scaffold with an impermeable
membrane made of expanded polytetraﬂuoroethylene (ePTFE). The
scaffold offers sufﬁcient radial force to create a sufﬁcient vessel wall
apposition and minimize post-deployment migration. Eight test de-
vices were deployed in the left renal arteries of four miniature swine.
Angiography was performed 1 and 10 minutes after device implanta-
tion. Follow-up angiography was obtained on day 30 (four devices)
and day 60 (four devices) prior to devices harvesting for histological
evaluation and biocompatibility assessment.
RESULTS All test devices were deployed as intended, and produced
complete and immediate vessel-occlusion. No clinical complications
were observed in the animals throughout the study course. No
recanalization, acute or chronic device migration was observed in
the renal arteries. Complete and durable vessel-occlusion without
any sign of recanalization and evidence of distal ischemia (renal
atrophy) was observed in all EOS devices during the follow-up
period.
CONCLUSIONS The EOS is a safe and reliable device resulting in im-
mediate and durable vessel occlusion in the renal arterial circulation
and evidenced by complete end organ ischemia.
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BACKGROUND Occasionally inferior vena cava (IVC) ﬁlters can
become occluded leading to signiﬁcant lower extremity morbidity.
Percutaneous endovenous intervention (PEVI) with different modal-
ities is the procedure of choice. Stents have been successfully used in
maintaining patency of the IVC ﬁlter which is often contracted and
ﬁbrosed. In this report we discuss the outcome of placement of
Wallstents in IVC ﬁlters at 28 5 months of follow-up.
METHODS We placed Wallstents in 37 patients who had presented
with chronic IVC ﬁlter occlusion. These stents were placed within or
adjacent to the occluded IVC ﬁlter. The patients had presented with
chronic bilateral lower extremity obstructive symptoms. Bilateral
popliteal venous access sites were used in all patients as the initial
approach. In 24 patients catheter directed thrombolysis was given
with t-PA for 18-28 hours. All patients were placed on indeﬁniteanticoagulation post-procedurally with rivaroxaban in 19 patients and
apixaban in 18. Aspirin at 81 mg was given to 34 of 37 patients for 6
months.
RESULTS The patients’ average age was 66 7 years. The duration
from IVC implantation was 5.7 2 years. Crossing the IVC ﬁlter was
from the popliteal vein in 31 patients and the right internal jugular
vein in 6. The adjacent space between the ﬁlter and IVC wall was
crossed in 9 and through the ﬁlter in 28 patients. Following placement
of a Wallstent, post dilatation to burst pressure was performed by a
high pressure balloon. The average diameter and length of the Wall-
stents were 16 0.7 X 739 mm. Within hours of PEVI, patients’
symptoms substantially improved. The stents were patent at a mean
follow-up of 28 5 months. There was no bleeding or recurrent
venous thromboembolic disease (VTE) during the procedure or at
follow-up.CONCLUSIONS The results demonstrate that juxta or intra IVC ﬁlter
stenting with a Wallstent is safe and effective in chronic IVC ﬁlter
occlusions. Furthermore administration of new oral anticoagulants
plus low-dose aspirin would prevent further IVC obstruction and VTE.
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